Safety and Tolerability of Oral OPC-34712 as Adjunctive Therapy in Adults With Major Depressive Disorder (the Orion Trial)
Status:
Completed
Trial end date:
2017-05-18
Target enrollment:
Participant gender:
Summary
To assess the long-term safety and tolerability of oral OPC-34712 (brexpiprazole), given in
addition to an FDA approved antidepressant (ADT) for the treatment of adults with Major
Depressive Disorder (MDD)
Phase:
Phase 3
Details
Lead Sponsor:
Otsuka Pharmaceutical Development & Commercialization, Inc.